Novo Nordisk was granted a patent for dual-drug pharmaceutical formulations.

{
  "signal_id": "46a8cdac-3f53-58e5-9d53-1bc92094f8b6",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-09-23T14:41:06+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "cpc": [
      {
        "code": "A61K 38/26"
      },
      {
        "code": "A61K 9/0019"
      },
      {
        "code": "A61K 9/08"
      },
      {
        "code": "A61K 31/4172"
      },
      {
        "code": "A61K 38/1703"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Healthcare Technology"
    ],
    "detail": "In September 2026 Novo Nordisk patented liquid formulations for co-administering semaglutide and cagrilintide through a dual-chamber device for diabetes and obesity treatment.",
    "summary": "Novo Nordisk was granted a patent for dual-drug pharmaceutical formulations.",
    "event_at": "2026-09-22",
    "inventors": [
      {
        "name": "Tommy Sander",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/tommysander"
      },
      {
        "name": "Christian Poulsen",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Rosa Rebecca Erritzoee Hansen",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-09-22",
    "source_url": "https://patents.google.com/patent/US12741013",
    "cpc_primary": {
      "code": "A61K 38/26"
    },
    "patent_title": "Pharmaceutical formulations",
    "patent_number": "US12741013",
    "uspto_assignee": "Novo Nordisk A/S",
    "patent_abstract": "Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.",
    "precision_class": "structural",
    "invention_explanation": "A paired liquid medicine designed to keep semaglutide and cagrilintide in separate chambers until they are delivered together to a patient.",
    "technologies_mentioned": [
      "pharmaceutical formulations",
      "semaglutide",
      "cagrilintide",
      "dual-chamber drug delivery"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/46a8cdac-3f53-58e5-9d53-1bc92094f8b6 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'